Feedback / Questions
EL-22 - PMGC Holdings
https://www.globenewswire.com/news-release/2025/04/24/3067373/0/en/Northstrive-Biosciences-Announces-Positive-FDA-Response-Supporting-A-Submission-of-IND-for-a-Phase-2-Clinical-Trial-for-EL-22-in-Combination-with-GLP-1-Receptor-Agonist-for-Obesity.html
Apr 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next